Qiming Venture Partners
China’s Hope Medicine raises $56m Series B
Chinese innovative drug company Hope Medicine has raised a $56 million Series B round jointly led by Qiming Venture Partners and Grand Flight Investment.
DCP, Sequoia lead Series B for China's Valgen Medtech
DCP Capital has continued its run of investments in China’s medical devices industry by participating in a Series B funding round for Hangzhou Valgen Medtech.
Qiming leads $30m Series B for China crypto start-up
Qiming Venture Partners has led a $30 million Series B round for China-based imToken, which claims to be Asia’s largest crypto wallet.
China consumer brands Genki Forest, Tasogare secure funding
Two emerging Chinese beverage brands - Genki Forest and Tasogare, which focus on sparkling water and coffee, respectively - have completed new funding rounds.
China's Zhihu completes $522m IPO, endures volatile debut
Chinese question-and-answer platform Zhihu endured a difficult New York Stock Exchange debut, closing at a 10.5% discount to its IPO price on a day when US-listed Chinese stocks fluctuated wildly.
China drug development outsourcer raises $70m
Zhenge Biotech – a Shanghai-based contract development and manufacturing organization (CDMO) for large molecule drugs – has raised $70 million in Series B funding led by Qiming Venture Partners and IDG Capital.
China's Connect Biopharma gains 8% on debut after $191m US IPO
Connect Biopharma, a China-headquartered drug developer specializing in treatments for T cell-driven inflammatory diseases, gained 8.8% on debut following a $191.3 million US IPO.
VCs commit $50m to China's Medilink Therapeutics
Suzhou Medilink Therapeutics, a Chinese biotech company specializing in antibody-drug conjugates (ADCs) commonly used as targeted therapies for treating cancer, has raised $50 million in Series A funding across two tranches.
China cancer screening business gains on Hong Kong debut
New Horizon Health, a China-based and venture capital-backed cancer early screening company, rose 215% on its trading debut following a HK$2 billion ($258 million) Hong Kong IPO.
Sequoia, Tencent lead Series E for China’s Miaoshou Doctor
Beijing Yuanxin Technology, operator of China-based online healthcare services platform Miaoshou Doctor, has raised RMB3 billion ($466 million) in Series E funding led by Sequoia Capital China and Tencent Holdings.
Qiming raises $441m for its sixth renminbi fund
Qiming Venture Partners has closed its sixth renminbi-denominate vehicle at RMB2.85 billion ($441 million), taking the firm's total assets under management to $5.9 billion.
Chinese financial education start-up raises $100m
Erwan Technology, a China-based wealth management education platform, has secured nearly $100 million in funding across Series D and E rounds.
China’s WeRide raises $310m
Chinese autonomous driving start-up WeRide has raised $310 million in Series B funding across three tranches led by Chinese electric bus manufacturer Yutong Group.
Carlyle leads $123m Series D for China's Abbisko
The Carlyle Group - investing through its Asia growth fund - has led a $123 million Series D round for Chinese cancer-focused biotech developer Abbisko Therapeutics.
VC-backed Chinese online tutor Xueba close to bankruptcy
Xueba100.com, a China-based one-to-one online tuition platform, has halted operations and is looking for industry peers to assume responsibility for its students and teachers.
The big C: China biotech start-ups get cutting edge on cancer
The evolution of cancer treatments in China is a bellwether for biotech development in the country and its capacity for genuine innovation. Most PE and VC investors aren’t shying away
Alibaba, Jeneration lead $196m round for China's Nice Tuan
Shihuituan, a China-based community group buying platform also known as Nice Tuan, has raised $196 million in the third tranche of a Series C round led by Alibaba Group and Jeneration Capital.
Sequoia leads $46m Series D for Chinese chip maker Yunyinggu
Yunyinggu, a Chinese manufacturer of integrated circuits used in flat screen displays, has raised RMB300 million ($46 million) in Series D funding led by Sequoia Capital China.
PE-backed Antengene trades flat after $359m HK IPO
Antengene, a China-based drug developer that previously raised $238 million across three private funding rounds, closed roughly flat on its first day of trading in Hong Kong following a HK$2.78 billion ($359 million) IPO.
Model behavior: China to Southeast Asia tech transplants
Plenty of internet start-ups in Southeast Asia have been inspired by Chinese forebears, but transplanting ideas from one market to another is often fraught with complications
Genor Biopharma raises $372m in Hong Kong IPO
China-based Genor Biopharma, which counts Hillhouse Capital, Temasek Holdings and Qiming Venture Partners among its investors, has raised HK$2.88 billion ($372 million) through a Hong Kong IPO.
China's InventisBio secures $147m Series D
GL Ventures, the China venture capital arm of Hillhouse Capital, has led a $147 million Series D round for Shanghai-based biotech developer InventisBio.
Fund focus: Qiming's cleantech team spins out, raises $73m fund
Inspiration Capital, a spinout from Qiming Venture Partners, has raised RMB500 million for its debut fund that focuses on cleantech and advanced manufacturing investments in China
Deal focus: Shukun stands out from the crowd
Shukun sought to differentiate itself from other Chinese artificial intelligence medical imaging start-ups by focusing on heart rather than lung conditions, but a COVID-19 diagnosis solution has given the company real traction